Valuation: Novartis AG

Market Cap 268B 238B 223B 202B 381B 25,846B 384B 2,675B 1,040B 13,185B 1,006B 985B 42,386B P/E 2026 *
19.9x
P/E 2027 * 16.7x
Enterprise Value 300B 266B 249B 226B 426B 28,881B 429B 2,989B 1,163B 14,734B 1,125B 1,100B 47,365B EV / Sales 2026 *
5.19x
EV / Sales 2027 * 4.83x
Free-Float
91.66%
Yield 2026 *
3.07%
Yield 2027 * 3.21%
1 day+1.07%
1 week-3.38%
Current month-1.25%
1 month-12.00%
3 months-9.45%
6 months-7.88%
Current year+2.12%
1 week 139.31
Extreme 139.31
142.5
1 month 137
Extreme 137
147.03
Current year 135.55
Extreme 135.55
170.46
1 year 121.57
Extreme 121.57
170.46
3 years 92.19
Extreme 92.19
170.46
5 years 74.09
Extreme 74.09
170.46
10 years 66.93
Extreme 66.93
170.46
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Compliance Officer 58 14/04/2025
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-3.38% - - 268B
+1.26%-2.29%+36.97%+104.79% 1,032B
+0.73%-4.78%+35.41%+61.62% 614B
+0.35%+1.29%+15.86%+79.90% 471B
+1.72%-4.92%+59.84%+36.64% 350B
+1.49%+1.29%+22.56%+40.96% 337B
+1.16%-1.40%+12.48%+34.21% 268B
+0.44%-2.61%-6.42%+10.17% 246B
-0.09%-4.97%+36.88%+50.52% 218B
-0.28%-4.66%+26.99%+92.98% 179B
Average +0.47%-3.39%+26.73%+56.87% 412.76B
Weighted average by Cap. +0.53%-3.18%+29.75%+67.17%

Financials

2026 *2027 *
Net sales 57.69B 51.21B 47.92B 43.44B 82.04B 5,561B 82.63B 576B 224B 2,837B 217B 212B 9,120B 61.39B 54.5B 51B 46.23B 87.3B 5,918B 87.93B 613B 238B 3,019B 230B 225B 9,706B
Net income 14.47B 12.85B 12.02B 10.9B 20.58B 1,395B 20.73B 144B 56.17B 712B 54.33B 53.17B 2,288B 16.1B 14.29B 13.37B 12.12B 22.89B 1,552B 23.05B 161B 62.46B 792B 60.42B 59.12B 2,545B
Net Debt 31.49B 27.96B 26.16B 23.71B 44.78B 3,036B 45.11B 314B 122B 1,549B 118B 116B 4,979B 28.29B 25.11B 23.5B 21.3B 40.23B 2,727B 40.52B 282B 110B 1,391B 106B 104B 4,472B
Projected Income Statement - Annual - Novartis AG
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
06/10/26 $140.79 -0.10% 1,574,426
05/10/26 $140.93 -0.05% 1,329,232
02/10/26 $141.00 -0.04% 2,246,667
01/10/26 $141.05 -1.07% 2,056,224
30/09/26 $142.57 -2.15% 3,062,096
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Novartis AG
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
141.06USD
Average target price
150.94USD
Spread / Average Target
+7.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Novartis AG